# Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study

**Authors:** Masaki Mitobe, Satoshi Shibuma, Haruhiko Takahashi, Jotaro On, Toru Takino, Keita Kawabe, Yoshihiro Mouri, Shunsuke Kumagai, Takashi Kozakai, Akihito Momoi, Naomi Suzuki, Takao Fukushima, Takaharu Suzuki, Hiroyuki Kuroda, Etsuji Saji, Kimihiko Nakamura, Hideki Hashidate, Asa Nakahara, Takahiro Tomita, Jun Watanabe, Yoshihiro Tsukamoto, Masayasu Okada, Tetsuya Hiraishi, Shinya Yamashita, Takuya Akai, Satoshi Kuroda, Akiyoshi Kakita, Hirohito Sone, Jun Takizawa, Makoto Oishi, Manabu Natsumeda

PMC · DOI: 10.1093/noajnl/vdaf274 · 2026-01-12

## TL;DR

This study shows that a non-surgical liquid biopsy can reliably detect PCNSL and guide treatment when surgery is not possible.

## Contribution

Demonstrates the feasibility of using liquid biopsy alone for PCNSL diagnosis and treatment initiation in non-operable cases.

## Key findings

- MYD88 L265P-mutant droplets were detected in all 10 patients via CSF cfDNA using ddPCR.
- Treatment response was observed in all patients diagnosed via liquid biopsy.
- Liquid biopsy helped rule out relapse in a patient with chronic renal failure.

## Abstract

The gold standard for the diagnosis of primary central nervous system lymphoma (PCNSL) remains surgical biopsy, but it carries the risk of complications, and operability depends on the size and location of the lesion or the patient’s condition. Previously, we have reported the reliable detection of MYD88 L265P-mutant droplets in cerebrospinal fluid (CSF) cell-free DNA (cfDNA) of PCNSL using droplet digital PCR (ddPCR). In the present study, we conducted a multi-institutional study to diagnose and initiate treatment for PCNSL by liquid biopsy alone without a surgical biopsy.

We analyzed 10 patients from 5 institutions who were deemed difficult to biopsy surgically and were subsequently treated based on the detection of MYD88 L265P-mutant droplets in their CSF cfDNA. CSF was obtained by lumbar puncture at each institution, cfDNA was extracted at Niigata University, and ddPCR was performed to detect MYD88 L265P-mutant droplets.

Surgical biopsy was not performed in 8 patients because the lesions were located in deep locations, such as the brainstem, and in 2 patients because of low performance status and/or advanced age. MYD88 L265P-mutant droplets were detected in all cases. Treatment response was observed in all cases. In a patient with chronic renal failure, liquid biopsy was helpful to rule out possible relapse.

Liquid biopsy for the diagnosis of PCNSL has the potential to replace surgical biopsy with a less-invasive method and early diagnosis, leading to early treatment and possibly better outcomes. Further large-scale studies are warranted to establish the reliability of this approach.

## Linked entities

- **Genes:** MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615]
- **Diseases:** primary central nervous system lymphoma (MONDO:0002571), chronic renal failure (MONDO:0024327)

## Full-text entities

- **Genes:** MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}
- **Diseases:** chronic renal failure (MESH:D007676), PCNSL (MESH:D008223)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** L265P

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978307/full.md

---
Source: https://tomesphere.com/paper/PMC12978307